Trials / Unknown
UnknownNCT05212896
An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors
An Exploratory Clinical Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BC006 Monoclonal Antibody Injection in Patients With Advanced Solid Tumors Including Giant Cell Tumor of Tendon Sheath
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Dragonboat Biopharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first in human, open-label, exploratory phase I clinical study including dose escalation (Ia) and dose expansion (Ib) stage. It aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BC006 in giant cell tumor of tendon sheath (GCTTS) and other advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BC006 | BC006 monoclonal antibody injection |
Timeline
- Start date
- 2021-11-26
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2022-01-28
- Last updated
- 2022-01-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05212896. Inclusion in this directory is not an endorsement.